These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Thiazole-derived potent, highly bioavailable short duration growth hormone secretagogues. Yang L; Morriello G; Leung K; Jacks T; Cheng K; Schleim KD; Smith R; Patchett AA Bioorg Med Chem Lett; 1999 Jul; 9(13):1761-6. PubMed ID: 10406638 [TBL] [Abstract][Full Text] [Related]
27. Ipamorelin, the first selective growth hormone secretagogue. Raun K; Hansen BS; Johansen NL; Thøgersen H; Madsen K; Ankersen M; Andersen PH Eur J Endocrinol; 1998 Nov; 139(5):552-61. PubMed ID: 9849822 [TBL] [Abstract][Full Text] [Related]
28. Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Patchett AA; Nargund RP; Tata JR; Chen MH; Barakat KJ; Johnston DB; Cheng K; Chan WW; Butler B; Hickey G Proc Natl Acad Sci U S A; 1995 Jul; 92(15):7001-5. PubMed ID: 7624358 [TBL] [Abstract][Full Text] [Related]
29. Preclinical pharmacology of CP-424,391, an orally active pyrazolinone-piperidine [correction of pyrazolidinone-piperidine] growth hormone secretagogue. Pan LC; Carpino PA; Lefker BA; Ragan JA; Toler SM; Pettersen JC; Nettleton DO; Ng O; Pirie CM; Chidsey-Frink K; Lu B; Nickerson DF; Tess DA; Mullins MA; MacLean DB; DaSilva-Jardine PA; Thompson DD Endocrine; 2001 Feb; 14(1):121-32. PubMed ID: 11322494 [TBL] [Abstract][Full Text] [Related]
30. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency. Svensson J; Monson JP; Vetter T; Hansen TK; Savine R; Kann P; Bex M; Reincke M; Hagen C; Beckers A; Ilondo MM; Zdravkovic M; Bengtsson BA; Korbonits M; Clin Endocrinol (Oxf); 2003 May; 58(5):572-80. PubMed ID: 12699438 [TBL] [Abstract][Full Text] [Related]
31. Bicyclic pyridones as potent, efficacious and orally bioavailable thrombin inhibitors. Coburn CA; Rush DM; Williams PD; Homnick C; Lyle EA; Lewis SD; Lucas BJ; Di Muzio-Mower JM; Juliano M; Krueger JA; Vastag K; Chen IW; Vacca JP Bioorg Med Chem Lett; 2000 May; 10(10):1069-72. PubMed ID: 10843219 [TBL] [Abstract][Full Text] [Related]
32. Rational design, discovery, and synthesis of a novel series of potent growth hormone secretagogues. Huang P; Loew GH; Funamizu H; Mimura M; Ishiyama N; Hayashida M; Okuno T; Shimada O; Okuyama A; Ikegami S; Nakano J; Inoguchi K J Med Chem; 2001 Nov; 44(24):4082-91. PubMed ID: 11708912 [TBL] [Abstract][Full Text] [Related]
33. New renin inhibitors containing pseudodipeptidic units in P3-P2 and P1-P1' positions. Paruszewski R; Jaworski P; Bodnar M; Dudkiewicz-Wilczyńska J; Roman I Chem Pharm Bull (Tokyo); 2005 Oct; 53(10):1305-9. PubMed ID: 16204988 [TBL] [Abstract][Full Text] [Related]
34. Effect of the Orally Active Growth Hormone Secretagogue MK-677 on Somatic Growth in Rats. Lee J; Kwon A; Chae HW; Lee WJ; Kim TH; Kim HS Yonsei Med J; 2018 Dec; 59(10):1174-1180. PubMed ID: 30450851 [TBL] [Abstract][Full Text] [Related]
35. Modulation on C- and N-terminal moieties of a series of potent and selective linear tachykinin NK(2) receptor antagonists. Gensini M; Altamura M; Dimoulas T; Fedi V; Giannotti D; Giuliani S; Guidi A; Harmat NJ; Meini S; Nannicini R; Pasqui F; Tramontana M; Triolo A; Maggi CA ChemMedChem; 2010 Jan; 5(1):65-78. PubMed ID: 19957262 [TBL] [Abstract][Full Text] [Related]
36. Endothelin antagonists: substituted mesitylcarboxamides with high potency and selectivity for ET(A) receptors. Wu C; Decker ER; Blok N; Bui H; Chen Q; Raju B; Bourgoyne AR; Knowles V; Biediger RJ; Market RV; Lin S; Dupré B; Kogan TP; Holland GW; Brock TA; Dixon RA J Med Chem; 1999 Nov; 42(22):4485-99. PubMed ID: 10579813 [TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetic and pharmacodynamic modeling of NN703, a growth hormone secretagogue, after a single po dose to human volunteers. Agersø H; Ynddal L; Søgaard B; Zdravkovic M J Clin Pharmacol; 2001 Feb; 41(2):163-9. PubMed ID: 11210396 [TBL] [Abstract][Full Text] [Related]
39. Molecular design and structure--activity relationships leading to the potent, selective, and orally active thrombin active site inhibitor BMS-189664. Das J; Kimball SD; Hall SE; Han WC; Iwanowicz E; Lin J; Moquin RV; Reid JA; Sack JS; Malley MF; Chang CY; Chong S; Wang-Iverson DB; Roberts DG; Seiler SM; Schumacher WA; Ogletree ML Bioorg Med Chem Lett; 2002 Jan; 12(1):45-9. PubMed ID: 11738570 [TBL] [Abstract][Full Text] [Related]